- Current report filing (8-K)
20 October 2009 - 3:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
October
16, 2009
BIO-BRIDGE
SCIENCE, INC.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
000-51497
|
20-1802936
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1211 West 22nd
Street, Suite 615, Oak Brook, Illinois
|
60523
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
630-928-0869
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
This
Form 8-K and other reports filed by the Registrant from time to time with the
Securities and Exchange Commission (collectively the “Filings”) contain forward
looking statements and information that are based upon beliefs of, and
information currently available to, the Registrant’s management as well as
estimates and assumptions made by the Registrant’s management. When
used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”,
“future”, “intend”, “plan” or the negative of these terms and similar
expressions as they relate to the Registrant or the Registrant’s management
identify forward looking statements. Such statements reflect the
current view of the Registrant with respect to future events and are subject to
risks, uncertainties, assumptions and other factors relating to the Registrant’s
industry, operations and results of operations and any businesses that may be
acquired by the Registrant. Should one or more of these risks or
uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.
Item
8.01 Other Events
As used
in this report, "we", "us", "our" or "BGES" refer to Bio-Bridge Science, Inc., a
Delaware corporation and its subsidiaries.
On
October 16, 2009, Bio-Bridge Science Inc. received a business license from the
Beijing Administration for Industry and Commerce of the PRC indicating approval
of the formation of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge
JRS”). Bio-Bridge JRS, is located in Beijing, China, and is
expected to commercially produce cell culture medium and related biomaterials
for use in scientific research and vaccine production.
Item
9.01 Financial Statements and Exhibits
(c) Exhibits.
Exhibit Number
|
|
Description
|
99.1
|
|
Press
release dated October 19, 2009
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIO-BRIDGE
SCIENCE, INC.
|
|
|
|
|
|
Date:
October
19, 2009
|
By:
|
/s/ Liang Qiao, MD.
|
|
|
Name
|
Liang
Qiao, MD.
|
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
|
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024